Steven Cohen Belite Bio, Inc Transaction History
Point72 Asset Management, L.P.
- $36.6 Billion
- Q3 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Belite Bio, Inc stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 4,800 shares of BLTE stock, worth $298,032. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,800
Previous 7,311
34.35%
Holding current value
$298,032
Previous $333,000
32.43%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding BLTE
# of Institutions
16Shares Held
79.1KCall Options Held
0Put Options Held
0-
State Street Corp Boston, MA20.1KShares$1.25 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC13.5KShares$835,1720.0% of portfolio
-
Marshall Wace, LLP London, X08.49KShares$526,8950.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.7KShares$416,0030.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il6.46KShares$401,1010.0% of portfolio
About BELITE BIO, INC
- Ticker BLTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,867,400
- Market Cap $1.54B
- Description
- Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...